Breyanzi Approved in Japan; but What’s the Price?

On Monday, March 22, Japan’s Ministry of Health Labour and Welfare (MHLW) approved Breyanzi (CD19 CAR-T) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed low-grade NHL, and high-grade B-cell lymphoma (press release). Below, Celltelligence provides insights on Breyanzi’s market access in Japan, while commenting on Breyanzi’s potential pricing and manufacturing strategies compared to key competitors Kymriah (Novartis) and Yescarta (Gilead).

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.